What Should All Physicians Know About Endovascular Stroke Care?

December 4, 2020
Endovascular stroke care is the criterion standard for LVO treatment, yet not everyone is fluent with data and techniques.  
0 Comments

Emergency Nursing Assessments, the NIHSS and Pitfalls in Identifying Acute Stroke Patients. How Do You Do It, and Do It Well?

December 4, 2020
Nurses in the emergency setting are the key to stroke patient progression. From first point of assessment and triage, ED nurses set the standard. 
0 Comments

What Pitfalls Do Clinicians Face In Understanding Statistics In Acute Stroke Trials?

December 4, 2020
Statistics can illuminate or obfuscate. Clinicians need to understand acute stroke trial data and statistics in meaningful ways, but challenges abound.
1 Comments

What Was Missing From the NINDS Trial?

December 4, 2020
The NINDS trial was the seminal study of IV-tPA in the treatment of acute stroke. Yet controversy still exists around the trial methodology and the interpretation of the data. Was anything missing from NINDS? Does it still resonate nearly 25 years later?
0 Comments

Mobile Stroke Units - Linking Ultra Early Care and Outcomes

December 2, 2020
Imagine a mobile stroke unit, with a CT scanner, arriving to care for stroke patients at the first point of medical contact. What are the possibilities and what are the data?
0 Comments
RSS
First123456810
Categories
More Entries

Sep 7

Why Is the Extended Window Controversial and What Happened With the FDA?

Haemin Go posted on 9/7/2021

Moderator: William A. Knight IV, MD, FACEP, FNCS
Other Participants: Stacie L. Demel, DO, PhD

The ECASS 3 trial was an RCT of IV-rtPA in the window of 3-4.5 hrs after onset of stroke symptoms. It was conducted in Europe. The European regulatory bodies have endorsed tPA for that window, but the FDA has not. Listen to two national experts in stroke discuss the trial and the meaning of the endorsement or lack thereof. This podcast is a must for acute stroke practitioners!

2 Comments
Tweet Share

2 comments on article "Why Is the Extended Window Controversial and What Happened With the FDA?"

Avatar image

Ken Milne

I watched the video on ECASS-III and you mentioned the controversy in this time window. However, there was no mention of Alper et al reanalysis in the BMJ_EBM that questioned the results? Can you comment? https://ebm.bmj.com/content/25/5/168


Avatar image

Ken Milne

Here was some of our feedback on Alper et al https://ebm.bmj.com/content/early/2020/08/10/bmjebm-2020-111517
Please login or register to post comments.
STAY CONNECTED
Let’s expand your stroke education network. Follow us on Twitter to get the latest updates about stroke education and stay up-to-date on hot topics in stroke care.
@stroke_journey
ABOUT THE STROKE JOURNEY
The Stroke Journey is an initiative developed by The National Stroke Education Center (NSEC) that strives to be the premier source of educational information for the diagnosis and treatment of stroke in the United States. NSEC extends the world-class educational expertise of the University of Cincinnati Department of Emergency Medicine and its partners via a variety of traditional and digital resources. NSEC and The Stroke Journey are dedicated to providing outstanding stroke education with timely material that mirrors the real-time changes in the medical education and stroke care landscape.
OUR PARTNERS
The Stroke Journey is a collaboration between the NSEC, EMCREG-International, and MedEd On The Go. Together we are committed to providing high-quality stroke education for healthcare professionals.
NSEC Sponsor Logo
EMREG Sponsor Logo
MedEd Sponsor Logo
Copyright 2024 The Stroke Journey | Privacy Policy | Terms of Use | Help & Support
Copyright 2024 The Stroke Journey
Privacy Policy | Terms of Use | Help & Support
Powered by MedEdOTG.com